AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16944408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15099314 — intervention group
Group type: EXPERIMENTAL
Intervention: Polidocanol (Aethoxysklerol)
Number of subjects: 25
Study 15099314 — intervention group
Group type: COMPARATOR
Intervention: Normal saline injections
Number of subjects: 25
Study 11738097 — intervention group
Group type: EXPERIMENTAL
Intervention: one 250 microg bolus + 250 microg/h infusion
Number of subjects: 174
Study 11738097 — intervention group
Group type: EXPERIMENTAL
Intervention: three 250 microg boluses + 250 microg/h infusion
Number of subjects: 174
Study 11738097 — intervention group
Group type: EXPERIMENTAL
Intervention: three 250 microg boluses + 500 microg/h infusion
Number of subjects: 174
Study 9228962 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (100,000 IU) with one dose of measles vaccine at age 9 months
Number of subjects: 462
Study 9228962 — intervention group
Group type: COMPARATOR
Intervention: No vitamin A supplementation with one dose of measles vaccine at age 9 months
Number of subjects: 462
Study 9228962 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (100,000 IU) with two doses of measles vaccine at ages 6 and 9 months
Number of subjects: 462
Study 9228962 — intervention group
Group type: COMPARATOR
Intervention: No vitamin A supplementation with two doses of measles vaccine at ages 6 and 9 months
Number of subjects: 462
Study 9228962 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (100,000 IU) with one dose of measles vaccine at age 9 months (boys)
Number of subjects: 462
Study 9228962 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (100,000 IU) with one dose of measles vaccine at age 9 months (girls)
Number of subjects: 462
Study 7965439 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-week regimen of benzathine penicillin G (1.2 million units every 3 weeks)
Number of subjects: 249
Study 7965439 — intervention group
Group type: COMPARATOR
Intervention: 4-week regimen of benzathine penicillin G (1.2 million units every 4 weeks)
Number of subjects: 249
Study 3656045 — intervention group
Group type: EXPERIMENTAL
Intervention: O'Neil suction cups
Number of subjects: 410
Study 3656045 — intervention group
Group type: COMPARATOR
Intervention: Malmström suction cups
Number of subjects: 410
Study 29635438 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab (n=149)
Number of subjects: 300
Study 29635438 — intervention group
Group type: COMPARATOR
Intervention: Control (n=151)
Number of subjects: 300
Study 26218586 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic immediate‐release (IR)/extended‐release (ER) oxycodone (OC)/acetaminophen (APAP) 7.5/325 mg tablets, total dose 15/650 mg every 12 hours for 4.5 days
Number of subjects: 96
Study 24637537 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone (1000 mg q.d.) plus low-dose prednisone (5 mg b.i.d.)
Number of subjects: 118
Study 24637537 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus prednisone
Number of subjects: 118
Study 22240264 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) mobilized PBMNCs
Number of subjects: 40
Study 22240264 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 21218679 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeding with oral support
Number of subjects: 20
Study 21218679 — intervention group
Group type: COMPARATOR
Intervention: Feeding without oral support
Number of subjects: 20
Study 18673000 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioabsorbable barrier
Number of subjects: 12
Study 18673000 — intervention group
Group type: COMPARATOR
Intervention: Non-resorbable barrier
Number of subjects: 12
Study 16179768 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam-padded gloves
Number of subjects: 11
Study 16179768 — intervention group
Group type: COMPARATOR
Intervention: Bare hands
Number of subjects: 11
Study 16179768 — intervention group
Group type: EXPERIMENTAL
Intervention: Air-bladder gloves
Number of subjects: 11
Study 14708875 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile electromagnetic field treatment (applied for 5 days, two times daily for 30 minutes, magnetic induction: 3 mT, frequency: 4 Hz)
Number of subjects: 42
Study 14708875 — intervention group
Group type: COMPARATOR
Intervention: Control group (pharmacological treatment only)
Number of subjects: 42
Study 10533300 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical latanoprost 50 micrograms/ml
Number of subjects: 26
Study 10533300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 8692625 — intervention group
Group type: EXPERIMENTAL
Intervention: pH-assisted placement technique
Number of subjects: 68
Study 8692625 — intervention group
Group type: COMPARATOR
Intervention: Standard placement technique
Number of subjects: 68
Study 1860093 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (2.5, 5, 10 or 20 mg bid for four weeks)
Number of subjects: 25
Study 1860093 — intervention group
Group type: COMPARATOR
Intervention: Placebo (four weeks)
Number of subjects: 25
Study 7106162 — intervention group
Group type: EXPERIMENTAL
Intervention: Methenamine mandelate granules 4 g/day alone
Number of subjects: 27
Study 7106162 — intervention group
Group type: EXPERIMENTAL
Intervention: Methenamine mandelate granules 4 g/day with ascorbic acid 4 g/day
Number of subjects: 27
Study 7106162 — intervention group
Group type: EXPERIMENTAL
Intervention: Methenamine mandelate granules 4 g/day with ascorbic acid 4 g/day plus cranberry cocktail 1/day
Number of subjects: 27
Study 7106162 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 27
Study 30794302 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone, 4 mg, orally twice daily (total daily dose 8 mg)
Number of subjects: 118
Study 30794302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 29389742 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment
Number of subjects: 4071
Study 29389742 — intervention group
Group type: COMPARATOR
Intervention: Control (discontinue all antihypertensive medications)
Number of subjects: 4071
Study 26426999 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal endoscope with a fluorescently labeled peptide
Number of subjects: 50
Study 25267661 — intervention group
Group type: EXPERIMENTAL
Intervention: Primaquine (30 mg)
Number of subjects: 16
Study 25267661 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (120/960 mg)
Number of subjects: 16
Study 25267661 — intervention group
Group type: EXPERIMENTAL
Intervention: Primaquine combined with dihydroartemisinin-piperaquine
Number of subjects: 16
Study 22464768 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 50
Study 22464768 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 50
Study 20719298 — intervention group
Group type: EXPERIMENTAL
Intervention: Bag-in-the-lens IOL
Number of subjects: 52
Study 20719298 — intervention group
Group type: COMPARATOR
Intervention: Control IOL (Alcon AcrySof SA60AT)
Number of subjects: 52
Study 17606664 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 15
Study 17606664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 16159655 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre‐incision infiltration of 1.5 ml local anesthetic mixture with general anesthesia (n=30)
Number of subjects: 90
Study 16159655 — intervention group
Group type: COMPARATOR
Intervention: Pre‐incision infiltration of 1.5 ml of 0.9% normal saline with general anesthesia (placebo, n=30)
Number of subjects: 90
Study 16159655 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia only (n=30)
Number of subjects: 90
Study 12220482 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery in patients with active IBD
Number of subjects: 30
Study 12220482 — intervention group
Group type: COMPARATOR
Intervention: Control group of healthy subjects
Number of subjects: 30
Study 10355910 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital and vitamin K
Number of subjects: 353
Study 10355910 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 353
Study 7492158 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow on formula milk containing 1.2 mg of iron per 100 ml
Number of subjects: 92
Study 7492158 — intervention group
Group type: COMPARATOR
Intervention: Follow on formula milk with no added iron
Number of subjects: 92
Study 7492158 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (with and without added iron)
Number of subjects: 92
Study 2056908 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (75-85% VO2max for 35-45 min three times per week for the last 2 months)
Number of subjects: 49
Study 2056908 — intervention group
Group type: COMPARATOR
Intervention: Resistance training (one set of 8-12 repetitions on ten Nautilus machines three times per week)
Number of subjects: 49
Study 7036276 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. cyclophosphamide (30 mg/kg) over a 6-day period
Number of subjects: 559
Study 7036276 — intervention group
Group type: COMPARATOR
Intervention: Control group (randomized)
Number of subjects: 559
Study 7036276 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall analysis
Number of subjects: 559
Study 30084414 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine + Tenofovir + EFV (TDF)
Number of subjects: 78
Study 30084414 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine + Adefovir + Zidovudine + EFV (ADV)
Number of subjects: 78
Study 28480270 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg
Number of subjects: 121
Study 28480270 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 300 mg
Number of subjects: 121
Study 28480270 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 26215172 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated-sprint (RS) training (EXP, 3 times week(-1), 18 maximal all-out 15-m sprints interspersed with 17 s of passive recovery)
Number of subjects: 18
Study 26215172 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON, n=9)
Number of subjects: 18
Study 23898691 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic tubes (ETs) attached to resistance training machines during knee extension exercise
Number of subjects: 22
Study 23898691 — intervention group
Group type: COMPARATOR
Intervention: Control group (without ETs)
Number of subjects: 22
Study 20058183 — intervention group
Group type: EXPERIMENTAL
Intervention: Appearance-focused intervention
Number of subjects: 362
Study 17531459 — intervention group
Group type: EXPERIMENTAL
Intervention: CP-CLA (400 mug chromium, 1.8 g CLA in 2.4 g tonalin oil, n=19)
Number of subjects: 35
Study 17531459 — intervention group
Group type: COMPARATOR
Intervention: Placebo (<0.1 microg Cr, 2.4 g canola oil, n=16)
Number of subjects: 35
Study 17531459 — intervention group
Group type: EXPERIMENTAL
Intervention: CP-CLA
Number of subjects: 35
Study 17531459 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 17531459 — intervention group
Group type: EXPERIMENTAL
Intervention: CP-CLA and Placebo
Number of subjects: 35
Study 16600640 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK‐4
Number of subjects: 12
Study 16600640 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 16600640 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticipatory Anxiety Challenge
Number of subjects: 12
Study 14649167 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to music during a 10-minute walk
Number of subjects: 30
Study 14649167 — intervention group
Group type: COMPARATOR
Intervention: Walking without music for 10 minutes
Number of subjects: 30
Study 11775548 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amphotericin B alone or combination with flucytosine therapy (Group I)
Number of subjects: 22
Study 11775548 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fluconazole alone or combination with flucytosine (Group II)
Number of subjects: 22
Study 11775548 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal amphotericin B plus intravenous amphotericin B with or without intravenous fluconazole followed by oral fluconazole or itraconazole (Group III)
Number of subjects: 22
Study 9056056 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (Anexate) 1 mg intravenously post bronchoscopy
Number of subjects: 22
Study 9056056 — intervention group
Group type: COMPARATOR
Intervention: Placebo intravenously post bronchoscopy
Number of subjects: 22
Study 8337995 — intervention group
Group type: COMPARATOR
Intervention: Group 1 (no ST segment depression)
Number of subjects: 1444
Study 8337995 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (transient ST segment depression)
Number of subjects: 1444
Study 8337995 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (persistent ST segment depression)
Number of subjects: 1444
Study 3541415 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg isosorbide-5-mononitrate (IS-5-MN) daily
Number of subjects: 12
Study 3541415 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 X 20 mg nifedipine retard daily
Number of subjects: 12
Study 3541415 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of both drugs for 2 weeks
Number of subjects: 12
Study 3541415 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 12
Study 3541415 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide-5-mononitrate (IS-5-MN)
Number of subjects: 12
Study 3541415 — intervention group
Group type: COMPARATOR
Intervention: Combination of both drugs
Number of subjects: 12
Study 30922018 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg) added to ISB with bupivacaine 0.3% and lidocaine 2%
Number of subjects: 60
Study 30922018 — intervention group
Group type: COMPARATOR
Intervention: Ketamine (50 mg) added to ISB with bupivacaine 0.3% and lidocaine 2%
Number of subjects: 60
Study 26277090 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol 300 mg twice daily
Number of subjects: 50
Study 26277090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 23943338 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-label thrombolysis
Number of subjects: 500
Study 23943338 — intervention group
Group type: COMPARATOR
Intervention: On-label thrombolysis (current European Alteplase license)
Number of subjects: 500
Study 23791822 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alteplase (0·9 mg/kg) plus standard care (n=1515)
Number of subjects: 3035
Study 23791822 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone (control; n=1520)
Number of subjects: 3035
Study 21111297 — intervention group
Group type: EXPERIMENTAL
Intervention: Group music activity (50-minute sessions, five times a week for 2 weeks)
Number of subjects: 67
Study 18203711 — intervention group
Group type: EXPERIMENTAL
Intervention: Panipenem
Number of subjects: 116
Study 18203711 — intervention group
Group type: COMPARATOR
Intervention: Cefepime
Number of subjects: 116
Study 16885388 — intervention group
Group type: EXPERIMENTAL
Intervention: ICSI children
Number of subjects: 304
Study 16885388 — intervention group
Group type: COMPARATOR
Intervention: SC children
Number of subjects: 304
Study 10825599 — intervention group
Group type: EXPERIMENTAL
Intervention: 30,000 IU vitamin A for 3 days just after each three doses of primary vaccination (Group I, n=24)
Number of subjects: 89
Study 10825599 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg oral vitamin E for only 1 day after the injections for primary immunization (Group II, n=21)
Number of subjects: 89
Study 10825599 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamins A and E together in the same order (Group III, n=21)
Number of subjects: 89
Study 10825599 — intervention group
Group type: COMPARATOR
Intervention: No vitamin after DPT vaccines (Group IV, n=23)
Number of subjects: 89
Study 9239812 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver nitrate
Number of subjects: 90
Study 9239812 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunisolide
Number of subjects: 90
Study 9239812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 1499480 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycemic index diet
Number of subjects: 6
Study 1499480 — intervention group
Group type: COMPARATOR
Intervention: High-glycemic index diet
Number of subjects: 6
Study 3907323 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release diltiazem 120 to 180 mg, 2 times a day
Number of subjects: 56
Study 3907323 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 25 to 50 mg, 2 times a day
Number of subjects: 56
Study 3907323 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of diltiazem and hydrochlorothiazide
Number of subjects: 56
Study 3907323 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 31026216 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis
Number of subjects: 489
Study 31026216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 489
Study 28851001 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention group received a psychoeducational treatment program after a 6-week introduction period alongside psychodynamic treatment.
Number of subjects: 0
Study 28851001 — intervention group
Group type: COMPARATOR
Intervention: Late intervention group received psychoeducation 3 months after starting psychodynamic treatment.
Number of subjects: 0
Study 26621183 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT with prolonged QRS duration (182.5 ± 16.2 msec)
Number of subjects: 80
Study 26621183 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT with LV leads located in the posterolateral vein
Number of subjects: 80
Study 26621183 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT with ΔQRS (QRS change)
Number of subjects: 80
Study 26621183 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT with biventricularly paced QRS
Number of subjects: 80
Study 24766760 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition to medication adoption
Number of subjects: 190
Study 24766760 — intervention group
Group type: EXPERIMENTAL
Intervention: Employment of at least one physician at baseline
Number of subjects: 190
Study 24766760 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater proportion of Medicaid clients
Number of subjects: 190
Study 24766760 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical detailing
Number of subjects: 190
Study 22573119 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (losartan/hydrochlorothiazide)
Number of subjects: 221
Study 22573119 — intervention group
Group type: COMPARATOR
Intervention: Maximal-dose ARB therapy
Number of subjects: 221
Study 19882338 — intervention group
Group type: EXPERIMENTAL
Intervention: Alumina-on-alumina ceramic bearings
Number of subjects: 150
Study 19882338 — intervention group
Group type: COMPARATOR
Intervention: Metal-on-highly cross-linked polyethylene bearings
Number of subjects: 150
Study 18628657 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba (EGb 761) 300 mg/d
Number of subjects: 62
Study 18628657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 16637714 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalometric method 1
Number of subjects: 25
Study 16637714 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalometric method 2
Number of subjects: 25
Study 12663296 — intervention group
Group type: EXPERIMENTAL
Intervention: Borage oil supplement (containing 100 mg GLA)
Number of subjects: 118
Study 12663296 — intervention group
Group type: COMPARATOR
Intervention: Sunflower oil supplement (placebo)
Number of subjects: 118
Study 11379464 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey
Number of subjects: 50
Study 11379464 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin/Honey mixture
Number of subjects: 50
Study 11379464 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 50
Study 8945040 — intervention group
Group type: EXPERIMENTAL
Intervention: VRS pacing algorithm
Number of subjects: 15
Study 8945040 — intervention group
Group type: COMPARATOR
Intervention: Control (50 ppm fixed rate pacing)
Number of subjects: 15
Study 1323954 — intervention group
Group type: EXPERIMENTAL
Intervention: Temafloxacin at 600 mg twice daily
Number of subjects: 246
Study 1323954 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin at 500 mg three times daily
Number of subjects: 246
Study 6394068 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 10 mgs bid administered during chemotherapy and continued in 43 patients for up to five years after termination of chemotherapy
Number of subjects: 124
Study 6394068 — intervention group
Group type: COMPARATOR
Intervention: No tamoxifen
Number of subjects: 124
Study 31685792 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin and metformin
Number of subjects: 36
Study 31685792 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride and metformin
Number of subjects: 36
Study 29070564 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsulated mustard
Number of subjects: 11
Study 29070564 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncapsulated mustard
Number of subjects: 11
Study 29070564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 25392325 — intervention group
Group type: EXPERIMENTAL
Intervention: GNbAC1 (2 or 6 mg/kg)
Number of subjects: 10
Study 25392325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 23279823 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-infrared spectroscopy (NIRS) during a working memory task
Number of subjects: 8
Study 23279823 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (N=16)
Number of subjects: 8
Study 21314870 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (15-30 mg/day)
Number of subjects: 60
Study 21314870 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine (10-20 mg/day)
Number of subjects: 60
Study 21314870 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 60
Study 21314870 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 60
Study 18485414 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraprostatic lidocaine injection
Number of subjects: 200